Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MK-8931

Novartis building

Novartis launches Alzheimer’s prevention study

Will test two treatments in people with genetic risk of dementia

- PMLiVE

Another Alzheimer’s failure as Targacept trial disappoints

Targacept drops development of drug after disappointing study results

- PMLiVE

Merck could win anti-PD1 therapy race in Europe

EMA accepts filing for promising pembrolizumab in melanoma

- PMLiVE

Merck & Co extends med ed portal to India

Pharma company makes Univadis accessible to yet more healthcare professionals

- PMLiVE

Merck agrees $3.85bn deal for hepatitis specialist Idenix

Opens up direct challenge to Gilead

- PMLiVE

AFFiRiS claims a first in Alzheimer’s disease therapy

Says AD04 is first drug to demonstrate disease modification

- PMLiVE

ASCO: Merck’s anti-PD1 impresses in skin and lung cancer

Promising MK-3475 immunotherapy to be known as pembrolizumab

- PMLiVE

Bruno Strigini leaves Merck & Co for Novartis

Will head up an oncology business boosted by the acquisition of GSK's portfolio

- PMLiVE

FDA grants priority review to Merck’s cancer antibody

Will speed up assessment of MK-3475 in skin cancer melanoma

- PMLiVE

Bayer buys Merck consumer health unit

Continues trend for major pharma deals

- PMLiVE

Merck’s vintafolide fails ovarian cancer trial

Major blow for drug’s original developers Endocyte

- PMLiVE

Reckitt Benckiser backtracks on Merck OTC unit

Ends negotiations to add to consumer health division

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links